JP7781052B2 - 神経学的疾患のための組成物および方法 - Google Patents

神経学的疾患のための組成物および方法

Info

Publication number
JP7781052B2
JP7781052B2 JP2022510971A JP2022510971A JP7781052B2 JP 7781052 B2 JP7781052 B2 JP 7781052B2 JP 2022510971 A JP2022510971 A JP 2022510971A JP 2022510971 A JP2022510971 A JP 2022510971A JP 7781052 B2 JP7781052 B2 JP 7781052B2
Authority
JP
Japan
Prior art keywords
receptor
ligand
pain
vector
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022510971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545226A5 (https=
JP2022545226A (ja
Inventor
アンソニー ジュニア ラウ，
オリオン ピー． ジュニア キーファー，
ステファニー マキンソン，
Original Assignee
トレイムス バイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トレイムス バイオ， インコーポレイテッド filed Critical トレイムス バイオ， インコーポレイテッド
Publication of JP2022545226A publication Critical patent/JP2022545226A/ja
Publication of JP2022545226A5 publication Critical patent/JP2022545226A5/ja
Priority to JP2024180241A priority Critical patent/JP2025004243A/ja
Application granted granted Critical
Publication of JP7781052B2 publication Critical patent/JP7781052B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022510971A 2019-08-21 2020-08-21 神経学的疾患のための組成物および方法 Active JP7781052B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180241A JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962889963P 2019-08-21 2019-08-21
US62/889,963 2019-08-21
PCT/US2020/047503 WO2021035179A1 (en) 2019-08-21 2020-08-21 Compositions and methods for neurological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024180241A Division JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022545226A JP2022545226A (ja) 2022-10-26
JP2022545226A5 JP2022545226A5 (https=) 2023-08-29
JP7781052B2 true JP7781052B2 (ja) 2025-12-05

Family

ID=72356519

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022510971A Active JP7781052B2 (ja) 2019-08-21 2020-08-21 神経学的疾患のための組成物および方法
JP2024180241A Pending JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024180241A Pending JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Country Status (7)

Country Link
US (1) US20220348635A1 (https=)
EP (1) EP4017874A1 (https=)
JP (2) JP7781052B2 (https=)
CN (1) CN114746450A (https=)
AU (1) AU2020334147A1 (https=)
CA (1) CA3151920A1 (https=)
WO (1) WO2021035179A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304040B2 (en) 2016-07-07 2024-09-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
SG11202004246YA (en) 2017-11-10 2020-06-29 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
IL300816A (en) * 2020-08-21 2023-04-01 Trames Bio Inc Preparations and methods for neurological diseases
US20250009906A1 (en) * 2021-11-19 2025-01-09 President And Fellows Of Harvard College Nociceptor-specific gene regulatory elements for the treatment of pain
EP4473002A4 (en) * 2022-01-31 2026-04-08 Hughes Howard Med Inst Modified ion channels sensitive to a ligand and methods of use
KR20240161957A (ko) * 2022-02-18 2024-11-13 트라메스 바이오 인코포레이티드 리간드 개폐 이온 통로 및 사용 방법
EP4514831A1 (en) * 2022-04-27 2025-03-05 Howard Hughes Medical Institute Chemogenetic receptors and methods of making and using
WO2025117698A1 (en) * 2023-12-01 2025-06-05 Massachusetts Institute Of Technology Ribozyme-enhanced rna trans-splicing

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009554A1 (en) 2002-05-09 2004-01-15 Memory Pharmaceuticals Corp. QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
US20060142188A1 (en) 2003-02-14 2006-06-29 Memory Pharmaceuticals Corporation Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof
US20090100532A1 (en) 2007-09-25 2009-04-16 California Institute Of Technology Transgenic mice expressing hypersensitive nicotinic receptors
JP2009189261A (ja) 2008-02-12 2009-08-27 Univ Fukuoka てんかんモデル非ヒト哺乳動物
JP2012504966A (ja) 2008-10-09 2012-03-01 ハワード ヒューズ メディカル インスティチュート 新規なキメラリガンド開口型イオンチャネルおよびその使用方法
WO2018175443A1 (en) 2017-03-20 2018-09-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted gene therapies for pain and other neuro-related disorders
WO2019094778A1 (en) 2017-11-10 2019-05-16 Scott Sternson Modified ligand-gated ion channels and methods of use
WO2019104307A1 (en) 2017-11-27 2019-05-31 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
AU8672198A (en) 1997-07-31 1999-02-22 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
DK1009808T3 (da) 1997-09-05 2013-01-21 Genzyme Corp Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
JP2003523320A (ja) 1999-09-29 2003-08-05 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途
TW200412942A (en) 2002-08-06 2004-08-01 Abbott Lab Appetite control method
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009554A1 (en) 2002-05-09 2004-01-15 Memory Pharmaceuticals Corp. QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
US20060142188A1 (en) 2003-02-14 2006-06-29 Memory Pharmaceuticals Corporation Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof
US20090100532A1 (en) 2007-09-25 2009-04-16 California Institute Of Technology Transgenic mice expressing hypersensitive nicotinic receptors
JP2009189261A (ja) 2008-02-12 2009-08-27 Univ Fukuoka てんかんモデル非ヒト哺乳動物
JP2012504966A (ja) 2008-10-09 2012-03-01 ハワード ヒューズ メディカル インスティチュート 新規なキメラリガンド開口型イオンチャネルおよびその使用方法
WO2018175443A1 (en) 2017-03-20 2018-09-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted gene therapies for pain and other neuro-related disorders
WO2019094778A1 (en) 2017-11-10 2019-05-16 Scott Sternson Modified ligand-gated ion channels and methods of use
WO2019104307A1 (en) 2017-11-27 2019-05-31 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases

Also Published As

Publication number Publication date
US20220348635A1 (en) 2022-11-03
CN114746450A (zh) 2022-07-12
EP4017874A1 (en) 2022-06-29
AU2020334147A1 (en) 2022-03-31
WO2021035179A1 (en) 2021-02-25
JP2025004243A (ja) 2025-01-14
JP2022545226A (ja) 2022-10-26
CA3151920A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
JP7781052B2 (ja) 神経学的疾患のための組成物および方法
JP2024160218A (ja) 神経疾患のための組成物および方法
JP2023538130A (ja) 神経疾患のための組成物および方法
JP2025508429A (ja) 神経学的疾患のための組成物および方法
JP2025508427A (ja) リガンド依存性イオンチャネルおよび使用の方法
BR122025015501A2 (pt) Receptor modificado, polinucleotídeo, vetor, uso dos mesmos, bem como método para expressão de um receptor modificado em um neurônio
CN119343455A (zh) 用于治疗癫痫和神经性疼痛的表达盒

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250424

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251125

R150 Certificate of patent or registration of utility model

Ref document number: 7781052

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150